{"Symbol": "HTBX", "AssetType": "Common Stock", "Name": "Heat Biologics, Inc", "Description": "Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "627 Davis Drive, Morrisville, NC, United States, 27560", "FullTimeEmployees": "36", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "194653968", "EBITDA": "-20375828", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.434", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.654", "RevenuePerShareTTM": "0.066", "ProfitMargin": "0", "OperatingMarginTTM": "-5.0806", "ReturnOnAssetsTTM": "-0.253", "ReturnOnEquityTTM": "-0.5943", "RevenueTTM": "3500600", "GrossProfitTTM": "-9964500", "DilutedEPSTTM": "-0.383", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.732", "AnalystTargetPrice": "5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "20.2745", "PriceToBookRatio": "4.4087", "EVToRevenue": "47.227", "EVToEBITDA": "0", "Beta": "0.8209", "52WeekHigh": "4.3", "52WeekLow": "0.195", "50DayMovingAverage": "1.9069", "200DayMovingAverage": "0.9601", "SharesOutstanding": "156979008", "SharesFloat": "143729373", "SharesShort": "1580735", "SharesShortPriorMonth": "1059385", "ShortRatio": "0.09", "ShortPercentOutstanding": "0.03", "ShortPercentFloat": "0.0356", "PercentInsiders": "6.037", "PercentInstitutions": "13.56", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:10", "LastSplitDate": "2018-01-22"}